Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
thats right j.... you know whats up... friggin mooorons have no clue around here....lite these mofos up
ur all good T.... let us all know what u find out...
Nymox Reports Safety Monitoring Committee Findings for Pivotal Phase 3 NX-1207
Trials
HASBROUCK HEIGHTS, N.J., July 28, 2010 (GLOBE NEWSWIRE) -- Nymox
Pharmaceutical Corporation (Nasdaq:NYMX) provided an update today on the
Company's Phase 3 program for NX-1207, Nymox's investigational drug for benign
prostatic hyperplasia (BPH). The Safety Monitoring Committee meeting of July
22, 2010 for the Phase 3 U.S. pivotal trials of NX-1207 was favorable and
indicated no significant safety concerns for the trials to date. Patient
recruitment and trial activities for pivotal U.S. studies NX02-0017 and
NX02-0018 are proceeding at over 70 well-known urology investigative sites
throughout the U.S.
NX-1207 has been shown to improve the signs and symptoms of BPH, producing
improvements which reached statistical significance compared to double-blinded
placebo and study controls. A single administration of NX-1207 2.5 mg has
produced on average improvements in the standardized BPH symptom score (8-10
points) that were approximately double that reported for currently approved
BPH drugs (3-5 points). The drug is administered by a urologist in an office
setting and involves little or no pain or discomfort. NX-1207 has not been
found to have the sexual, blood pressure, or other side effects of the
approved drugs. Follow-up studies have shown clinical efficacy effects in men
lasting up to 5 years after a single treatment.
Recent positive data on NX-1207 was presented at a symposium and panel
discussion held at the Annual Meeting of the American Urological Association
in San Francisco in June. The well-attended symposium highlighted the ongoing
clinical development program for NX-1207 for the treatment of benign prostatic
hyperplasia (BPH) and featured expert panel discussions on the new therapy.
The symposium, "Progress with NX-1207: Phase 3 Pro-Apoptotic Injectable for
BPH," was chaired by Neal Shore, MD, FACS of Myrtle Beach, SC. Panel members
included Barrett Cowan, MD, FACS of Denver, CO, Barton Wachs, MD, FACS of Long
Beach, CA, and Chris Threatt, MD of Atherton, CA, and included a new research
report authored by Dr. Barrett Cowan, Dr. Kevin Cline of Shreveport, LA, Dr.
Sheldon Freedman of Las Vegas, NV, Dr. Pat Hezmall of Arlington, TX, Dr.
Barton Wachs, Dr. Chris Threatt, and Dr. Neal Shore. According to the report
"NX-1207 is an office-based procedure involving only a few minutes to
administer associated with minimal discomfort and no catheter requirement,"
and "results indicate statistically significant symptomatic improvement and a
very acceptable safety profile." According to Dr. Shore, a well known U.S.
clinical investigator and expert in prostate diseases, "If approved, NX-1207
will certainly change the landscape of how we treat BPH symptoms and would set
the standard for office-based therapy for BPH."
BPH is one of the most commonly diagnosed diseases in the male U.S.
population. The condition can seriously impact the health and quality of life
of older men and can lead to acute urinary retention, incontinence, and other
serious consequences. It is estimated that 50% of men in their 50s have
pathological signs of prostatic hyperplasia and from 26 to 46% of men between
the ages of 40 to 79 years suffer from moderate to severe urinary problems and
symptoms associated with BPH.
no i do not.
yes gotta love the move this has made but better yet the recognition this co. is now getting. the vol the last week and today is very strong...like i said this stk is on the take right now and of course expect it to back and fill but the product they have nx-1207 is making at least one research firm do something that has never happened that i know of in the past...and thats being covered...they themselves put and 11 tag on the stk on investor awareness alone....not to get to ahead of ourselves but when it does hit radars this stk is so thin it will make big moves. as long as the product continues to impress as it has with many doctors thats great news.....take a look at bloomberg if you dont already and look at some of the past articles regarding what some urologists have been quoted saying...they like what they see....gl
day
gotta love the action of this skt last week and today blowing thru the 200. the fact that there is a research firm covering them now is huge and this is the reason for the recent move i would think. many years ago a friend of mine noted this could be a takeover canadite which never happend but many months ago it was said from a newsletter,which i believe was motley fool that this skt could be a potential takeover play....i dont pay any attention to motely for the record but found that interesting when i was told about it. not sure if it was earlier this year or late last year but my dad had spoke with the ceo for quite sometime and it was said that the phase 3 trials could last years but there was progress...progress, coupled with coverage now will bring this very thin stk to the attention of those who never heard of this co who manage HC portfilios. all the vol last week has been on the take and a position or positions are being built... by whom not sure. i love that the coverage comes from the same area i believe as NYMX itself. i expect this stk to hit the radar and like what i have seen as of late....well i just looked at the last 4.53 what a day!!! love the conviction on the vol...there should be a headline put out on this breaking thru the 200 confirmed by vol very soon i would expect...gl
HASBROUCK HEIGHTS, N.J., July 21, 2010 (GLOBE NEWSWIRE) -- Singular Research
has initiated coverage of Nymox Pharmaceutical Corporation (Nasdaq:NYMX) with
a "Buy" rating and a 12 month target price of $11.00. The report was written
by Gregory P. Garner, CFA, an equity research analyst for Singular Research.
According to the report, "Nymox Pharmaceutical is a pharmaceutical development
company with a very promising compound for enlarged prostate that is in Phase
3 clinical trials…several anticipated events in the coming 12 to 18 months
will lead to greater investor awareness of the product and push valuations
upwards, in our opinion."
this off bloomberg.....
hey fed i just got this email...
Bank of America in SEC Filing: Exposure to PIIGS (16.19 -0.09)
Greece Exposure: $1.299 bln ($193 mln sovereign, $1.106 bln non-Sovereign); Ireland $5.193 bln (S- $401 mln, NS- $4.79 bln); Italy $9.643 bln (S- $2.335 bln, NS - $7.308 bln); Portugal $731 mln (S- $33 mln, NS- $698 mln); Spain $5.682 bln (S- $122 mln, NS- $5.56 bln.
you got it fed and thx.... have a good day all..its 5 o'clock somewhere so im outta here
appreciated FW...now dont you have a few errands to run?? i for one would like to see a bounce in this today..hahah just messin
sI just wanna say thx for what u do on this board i know u really make a huge effort to educate and gotta give u props and kettle thx for the app update...also, as far as my word on the street i spent 13 yrs in the industry, still have a family member and many friends in the biz who keep me up on things and wanted to share what i had heard as im sure most people were scrambling wondering WTF was going on yesterday
right now the euro is moving higher as there is a story going around....Story about 600bn EUR ECB loan facility to be announced over weekend
1yr. 1% to to cover 1100 banks ... this story came from a friend on the NYSE and another friend upstairs and has been circulating for a little while but i have been busy doing other things and didnt get it out there when i heard....what this means tho is IF this happens we should rally...again we will know over the weekend what the dilio really is
sorry for the post not relating to this stk i know thats what the board is for. as far as the broader mkt itself i dont think it has anything to do with the stk
(mrnj) whatsoever...im long this thing and love what potential this has. i hope it all pays off for us oneday. gl to all
hey guys
this is my first post on ihub. i own this stk and love it. anyway the rumor on the street is that citi had a $16mil sell program and was taken as $16bil....none of these trades will stand most likely